To Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of STR-P004

Summary

This is a single-arm, single-center, open-label, multiple-dose, dose-escalation early clinical study aimed at evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary antitumor activity of STR-P004 in subjects with relapsed/refractory CD19-positive acute lymphoblastic leukemia.

Timeline

Start

2025-12-03

Primary completion

2026-11-02

Completion

2026-12-30

Drugs

Indications